Menu

PRESS RELEASES


Björn Westberg to join BONESUPPORT™ as Chief Financial Officer

21st December

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board

16th December

Richard Davies Wins “Best CEO in the Biomaterials Industry” Award from European CEO Magazine

13th December

BONESUPPORT™ Announces Key Corporate Appointment To Drive Growth in North America

7th November

BONESUPPORT™ Raises $37 Million (SEK 327 million) to Drive Product Sales and Deliver Further Value From CERAMENT® Injectable Drug Eluting Bioceramic Platform

27th October

BONESUPPORT™‘s CERAMENT®|G Highly Effective Adjunct in the Single Stage Surgical Management of Chronic Osteomyelitis

1st September

BONESUPPORT™‘s CERAMENT®|G and CERAMENT® V to be Featured Extensively at the 35th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) in Oxford, UK

30th August

BONESUPPORT™ Receives FDA Approval to Initiate IDE Clinical Study

9th August

BONESUPPORT™ Announces Nature Publication of Pre-Clinical Study Highlighting CERAMENT®’s Attractive Bone Remodeling Properties and as a Local Drug Delivery Platform for Bone Disease

1st June

BONESUPPORT® Announces Availability in Europe of CERAMENT™|G in 5 mL Volume to Address Growing Market Demand

1st March

BONESUPPORT™ Reports Expansion of Company's CERAMENT® Drug Eluting Procedure Registry

2nd February

BONESUPPORT™ Announces Appointment of Life Sciences Industry Veteran, Richard Davies, as New Chief Executive Officer

22nd January

BONESUPPORT™ Announces 20,000 Patients Now Treated with CERAMENT®

11th January

BONESUPPORT™ Announces CERAMENT® Focused Research Collaboration with Rigshospitalet, Copenhagen University Hospital

7th January

BONESUPPORT™ Announces Positive Data Highlighting the Use of CERAMENT®|G in the Management of Osteomyelitis in the Infected Diabetic Foot

5th January

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th December 2017

BONESUPPORT™ ACHIEVES AIM OF RECRUITING 136 PATIENTS INTO THE CERTiFy STUDY COMPARING CERAMENT®|BONE VOID FILLER WITH AUTOGRAFT

13th December 2017

BONESUPPORTTM OPENS ITS NEW HEAD QUARTERS

12th December 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

30th November 2017

BONESUPPORT HOLDING AB (publ) NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2018 APPOINTED

22nd November 2017

BONESUPPORTTM SIGNS COMMERCIALIZATION AGREEMENT FOR THE ITALIAN MARKET

20th November 2017

BONESUPPORTTM - CERAMENT® G’s POTENTIAL TO PREVENT AND MANAGE BIOFILM-RELATED BONE INFECTIONS HIGHLIGHTED IN NEW HIGH-PROFILE PUBLICATION

14th November 2017

BONESUPPORT HOLDING AB (publ) – Interim Report – January – September 2017

2nd November 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st October 2017

BONESUPPORT HOLDING AB (publ) – Q3 2017 Interim Report – invitation to conference call and webcast

19th October 2017

BONESUPPORTTM APPOINTS HELENA L BRANDT AS HEAD OF HUMAN RESOURCES

13th October 2017

BONESUPPORTTM – First Patient Recruited in Study Evaluating CERAMENT® G and CERAMENT® V in Patients Undergoing Hip and Knee Arthroplasty Revisions

9th October 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th September 2017

BONESUPPORT™ – DATA PRESENTED AT THE EUROPEAN ORTHOPAEDIC RESEARCH SOCIETY MEETING HIGHLIGHTS CERAMENT® BONE VOID FILLER (BVF) ABILITY TO ELUTE DRUGS WITH THE POTENTIAL TO ENHANCE BONE GROWTH

20th September 2017

BONESUPPORT APPOINTS JERRY CHANG AS EXECUTIVE VICE PRESIDENT OF RESEARCH & DEVELOPMENT

19th September 2017

BONESUPPORT™ SIGNS COMMERCIALIZATION AGREEMENT FOR THE FRENCH MARKET

7th September 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st August 2017

BONESUPPORT HOLDING AB (publ) - Interim Report January - June 2017

17th August 2017

BONESUPPORT™ - Q2 2017 Interim Report – invitation to conference call and webcast

11th August 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st July 2017

Exercise of over-allotment option and end of the stabilization period

21st July 2017

Stabilization notice

17th July 2017

BONESUPPORT™ - Pipeline Project Targeting Bioceramics Capable of Enhancing Bone Growth Awarded SEK 8 million Grant from Vinnova Sweden

12th July 2017

Stabilization notice

5th July 2017

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

30th June 2017

Final price in BONESUPPORT™’s initial public offering set at SEK 29 per share – trading on Nasdaq Stockholm commences today

21st June 2017

BONESUPPORT™ Announces First Patient Enrolled in FORTIFY Trial with CERAMENT®|G, a novel injectable, antibiotic-eluting bone graft substitute

22nd May

Lennart Johansson to join BONESUPPORT™ Board of Directors

28th April

BONESUPPORT™ appoints Michael Diefenbeck as Chief Medical Officer

11th April

BONESUPPORT™ Founder Lars Lidgren Receives the 2017 OREF Clinical Research Kappa Delta Award

16th March

BONESUPPORT™ Extends U.S. Distribution Agreement for CERAMENT®|BONE VOID FILLER

14th March

BONESUPPORT CEO to present at the Medtech Showcase 2017, in conjunction with the 9th Annual Biotech Showcase™

6th January

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

28th December 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

30th November 2018

BONESUPPORT - POSITIVE RESULTS FROM THE CERTiFy STUDY COMPARING CERAMENT®|BONE VOID FILLER WITH AUTOGRAFT

19th November 2018

BONESUPPORT HOLDING AB (publ) – Interim Report

7th November 2018

BONESUPPORT HOLDING AB (publ) – Q3 2018 Interim Report – invitation to conference call and webcast

1st November 2018

BONESUPPORT starts selling CERAMENT® BONE VOID FILLER Direct in the US via its own New Distributor Network

22nd October 2018

BONESUPPORT to Showcase CERAMENT® BONE VOID FILLER at Two Upcoming US Orthopedic Conferences

8th October 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

28th September 2018

BONESUPPORT highlights significant strategic progress at Capital Market Days in Stockholm and London

19th September 2018

BONESUPPORT to be Featured at the Annual Meeting of the European Bone & Joint Infection Society (EBJIS)

6th September 2018

Invitation BONESUPPORT Capital Markets Days

5th September 2018

Save the date: BONESUPPORT Capital Markets Days to be held in Stockholm and London

24th August 2018

BONESUPPORT - CERAMENT® G Approved by Health Canada

16th August 2018

BONESUPPORT Signs Agreement with MTF Biologics to Expand US Product Offering

2nd August 2018

BONESUPPORT HOLDING AB (publ) – Interim Report

26th July 2018

Q2 2018 Interim Report – invitation to conference call and webcast

23rd July 2018

BONESUPPORT appoints Michael Diefenbeck as Head of Research & Development, Medical and Clinical Affairs

18th July 2018

Håkan Johansson to start as BONESUPPORT’s CFO at the end of 2018

4th July 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th June 2018

BONESUPPORT provides update on US orders of CERAMENT BVF

21st June 2018

BONESUPPORT to significantly expand its European sales organization

29th May 2018

BONESUPPORT Signs Strategic Agreement with Collagen Matrix, Inc. to Expand Product Offering in the US

24th May 2018

BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 22 MAY 2018

22nd May 2018

BONESUPPORT creates its own US Commercial Platform

17th May 2018

BONESUPPORT HOLDING AB (Publ) – Q1 Interim Report

4th May 2018

BONESUPPORT HOLDING AB (publ) publishes Annual Report 2017

30th April 2018

BONESUPPORT HOLDING AB (publ) – Q1 2018 Interim Report – invitation to conference call and webcast

27th April 2018

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB

20th April 2018

BONESUPPORT™ – Positive clinical data for CERAMENT® G in infection management presented at BLRS 2018

21st March 2018

BONESUPPORT’s New CEO Purchases Shares

13th March 2018

BONESUPPORTTM to present at Orthopaedic Research Society (ORS) 2018 Annual Meeting

9th March 2018

BONESUPPORT™ to present at Canaccord Musculoskeletal Conference

5th March 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

28th February 2018

BONESUPPORT™ HOLDING AB (Publ) – Q4 and 2017 Year-End Report – January – December

20th February 2018

BONESUPPORT HOLDING AB – Year-end Report January-December 2017 – invitation to conference call and webcast

6th February 2018

BONESUPPORT™ repays outstanding loan from Kreos

1st February 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31st January 2018

Emil Billbäck appointed CEO of BONESUPPORT

23rd January 2018

PUBLICATION HIGHLIGHTS A NOVEL CERAMENT® CARRIER WITH BONE ACTIVE AGENTS ENHANCING BONE FORMATION

22nd January 2018

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

31 July 2019

BONESUPPORT HOLDING AB (publ) – Publishes Q2 2019 Interim report

25 July 2019

Item affecting comparability in Q2 2019

19 July 2019

BONESUPPORT HOLDING AB (publ) – Q2 2019 Interim Report – invitation to conference call and webcast

18 July 2019

BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 14 MAY 2019

14th May 2019

BONESUPPORT HOLDING AB (publ) – Published Q1 2019 Interim report

2nd May 2019

BONESUPPORT HOLDING AB (publ) – Q1 2019 Interim Report – invitation to conference call and webcast

25th April 2019

BONESUPPORT - Change in the management team

24th April 2019

BONESUPPORT HOLDING AB (publ) publishes Annual Report 2018

17th April 2019

BONESUPPORT will publish quarterly report earlier than previously communicated

16th April 2019

NOTICE OF ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB

12th April 2019

ACTIVE REMODELING OF CERAMENT® INTO HUMAN BONE CONFIRMED IN UK STUDY

10th April 2019

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

29th March 2019

BONESUPPORT LAUNCHING A NEW PRODUCT - BONIFY - US PRODUCT PORTFOLIO EXPANSION

13th March 2019

Issue and repurchase of series C shares for share saving programs

1st March 2019

BONESUPPORT HOLDING AB (publ) – Full Year Report 2018

27th February 2019

BONESUPPORT – Publication of a clinical study highlighting Vancomycin release from CERAMENT® V in major hip surgery

22nd February 2019

BONESUPPORT HOLDING AB (publ) – Invitation to conference call in connection of the Full Year Report 2018

20th February 2019

Correction of error Q3 (18) report

13th February 2019

BONESUPPORT – Publication of pre-clinical study highlighting unique bone remodeling qualities of CERAMENT® in large bone defects

8th February 2019

BONESUPPORTTM and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting

1st February 2019

BONESUPPORT appoints Annelie Aava Vikner as Executive Vice President Global Marketing & Communications

4th January 2019

BONESUPPORT™ Raises $37 Million (SEK 327 million) to Drive Product Sales and Deliver Further Value From CERAMENT® Injectable Drug Eluting Bioceramic Platform

- Dr. Håkan Björklund of Tellacq AB, former CEO of Nycomed, becomes Chairman-Elect   

- CERAMENT™ BVF, CERAMENT™ G AND CERAMENT™ V continue to increase sales rapidly driven by a growing body of compelling clinical data

Lund, Sweden, 27 October, 2016 - BONESUPPORT AB an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that it has raised $37 million (SEK 327 million) in a combination of equity and debt finance. These new funds will be used to deliver further value from its unique CERAMENT™ platform. The oversubscribed equity financing was led by Tellacq AB and was supported by the Company's current major shareholders, including HealthCap, Lundbeckfond Ventures, Industrifonden, AP3 (The Third Swedish National Pension Fund) and Carl Westin. The debt finance was provided by Kreos Capital.

Dr. Håkan Björklund of Tellacq AB will be joining the BONESUPPORT Board as Chairman in conjunction with the fund raising, subject to shareholder approval. Dr. Björklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global business before its acquisition by Takeda in 2011. He is currently chairman of the board of Swedish Orphan Biovitrum AB and an Industry Executive at Avista Capital Partners.

Richard Davies, CEO of BONESUPPORT said, "I am delighted that we have been able to complete this new financing to help us to execute our strategy to deliver the significant potential of our unique CERAMENT™ drug eluting osteoconductive/osteoinductive bioceramic platform. I am also pleased that the equity element reflects the significant progress that we have made during the course of 2016. With our sales on a strong growth trajectory, an increasing body of compelling clinical data and a drug eluting platform that will allow us to develop a pipeline of novel products to treat a broad range of bone diseases, BONESUPPORT can look to the future with great confidence."

"We are delighted to welcome Håkan Björklund to the board at this exciting time for the company and look forward to benefiting from his extensive experience in the years ahead. I would also like to take this opportunity to thank the departing chairman Dr. Örn Stuge for his significant contribution to BONESUPPORT over many years" says Björn Odlander, Managing Partner at HealthCap and board member.

Håkan Björklund, said: "Our decision to invest in BONESUPPORT was driven by the important progress that has been made over recent years. The CERAMENT™ drug eluting platform offers multiple opportunities to generate significant value by providing much needed and cost-efficient treatment options for patients with a broad range of bone diseases. I look forward to working with the management team and the Board to deliver BONESUPPORT's potential to become a global leader in the management and treatment of bone disease." 

The new funds will be used to support the execution of BONESUPPORT's strategy to deliver significant shareholder value, focused on:

- Driving the sales of CERAMENT™ BVF, CERAMENT™ G and CERAMENT™ V in existing and new markets

- Generating further clinical data to highlight the compelling benefits that the current CERAMENT™ products deliver and to conduct the FORTIFY study to support a planned PMA filing in the US for CERAMENT™ G

- Building the Company's product pipeline by capitalizing on the unique drug eluting properties of its injectable osteoconductive/osteoinductive bioceramic platform.

In the first half of 2016, BONESUPPORT's overall sales have continued to grow rapidly driven by the European success of CERAMENT™ G and CERAMENT™ V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products are used for the management of problematic bone infections including osteomyelitis and prophylactically in patients who are at risk for developing infection. Sales of CERAMENT™ BVF have also shown good growth as the product has continued to gain traction in the US where it is marketed by BONESUPPORT's partner Zimmer Biomet.

BONESUPPORT is also continuing to generate the clinical data needed to drive the adoption of its products. A recent paper in The Bone and Joint Journal[1] provided follow up data from the first 100 patients in a prospective study evaluating CERAMENT™ G for dead space (void) management in patients with chronic osteomyelitis (bone infection) using a single stage surgical procedure. These data showed that this approach, augmented by the use of CERAMENT™ G, was highly effective, delivering a 96% prevention of infection recurrence rate, a 3.0% fracture rate and a total wound leakage rate of 6.0%. This represents a significant improvement in both the infection recurrence and fracture rates when compared to published results evaluating alternative bone graft substitutes that deliver antibiotics locally.

The Company has also recently received approval from the US Food and Drug Administration (FDA) to begin an IDE (Investigational Device Exemption) study with CERAMENT™ G. The FORTIFY study, a randomized multicenter controlled trial, which will evaluate the safety and efficacy of CERAMENT™ G as part of surgical repair of open diaphyseal tibial fractures. The first patient is expected to be recruited into this prophylactic study before the end of 2016.

BONESUPPORT will also use the funds to develop its product pipeline. The Company believes that the attractive properties of its CERAMENT™ platform will allow it to develop products that will deliver a broad range of drugs to the bone to manage indications including osteoporosis, cancer and pain.

References

1. McNally et al, The Bone and Joint Journal, 2016, Vol. 98-B, No. 9, p1289-9

2. Raina, D. et al. A Biphasic Calcium Sulfate Hydroxapatite Carrier Bone Morphogenic Protein -2 and Zoledronic Acid Generates Bone (2016) Nature Scientific Reports

 

Ends

Notes to Editor

 

About BONESUPPORT™

BONESUPPORT AB has developed CERAMENT™ as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT™|BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT|BVF is commercially available in the U.S., EU, S.E. Asia and the Middle East.

CERAMENT's distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT™|G and CERAMENT™ V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT|G and CERAMENT™ have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT|G and CERAMENT™ V are available in the EU.

BONESUPPORT AB was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT’s mission is to bring people with bone and joint diseases back to an active life. The company is based in Lund, Sweden.

bonesupport.com

BONESUPPORT™ is a registered trademark.

Contact Information

Citigate Dewe Rogerson

David Dible, Andrea Bici, Mark Swallow

+44 (0)20 7282 2949/1050/2948

Downloads

Press release PDF (130.84 KB)

BONESUPPORT, Fri Aug 2, 2019

@MSIS 2019 CERAMENT Bone Void Filler injectable bone graft substitute remodels to bone 6-12 months. Meet… https://t.co/vbLgu854rt

BONESUPPORT, Fri Aug 2, 2019

@BONESUPPORT_AB is exhibiting at the MSIS congress NYC. Hear more about CERAMENT G resorbable injectable antibiotic… https://t.co/JJ8wURMyNT

BONESUPPORT, Thu Mar 21, 2019

Busy first day at @OBIC! Come a meet BONESUPPORT tomorrow and learn more about CERAMENT G and V. https://t.co/Ulc3BGPgIF